WT1 Expression in Patients with Myelodysplastic Syndromes: A Variety of Possibilities in Future Clinical Practice

Publisher： Karger

E-ISSN： 1421-9662|137|1|30-31

ISSN： 0001-5792

Source： Acta Haematologica, Vol.137, Iss.1, 2016-11, pp. : 30-31

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Wilms Tumor 1 (WT1) mRNA Expression Level at Diagnosis Is a Significant Prognostic Marker in Elderly Patients with Myelodysplastic Syndrome

By  

Acta Haematologica, Vol. 137, Iss. 1, 2016-11 ,pp. : 32-39

Karger

Access to resources Recommend Favorite

CSNK1A1 mutations and gene expression analysis in myelodysplastic syndromes with del(5q)

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 7-1048, Iss. 2, 2015-10 ,pp. : 210-214

John Wiley & Sons Inc

Access to resources Recommend Favorite

CSNK1A1 mutations and gene expression analysis in myelodysplastic syndromes with del(5q)

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 171, Iss. 2, 2015-10 ,pp. : 210-214

John Wiley & Sons Inc

Access to resources Recommend Favorite

Danazol Therapy for Thrombocytopenia in Patients with Myelodysplastic Syndromes

By  

Acta Haematologica, Vol. 107, Iss. 4, 2002-05 ,pp. : 234-236

Karger

Access to resources Recommend Favorite

Darbepoetin alfa for anemia in patients with low or intermediate-1 risk myelodysplastic syndromes and positive predictive factors of response

By Villegas A.   Arrizabalaga B.   Fernáández-Lago C.   Castro M.   Mayans J.R.   Gonzáález-Porras J.R.   Duarte R.F.   Remacha A.F.   Luñño E.   Gasquet J.A.  

Current Medical Research and Opinion, Vol. 27, Iss. 5, 2011-05 ,pp. : 951-960

Informa Healthcare

Access to resources Recommend Favorite